Cargando…

Bevacizumab for Macular Serous Neuroretinal Detachment in Tilted Disk Syndrome

Background. Tilted disc syndrome (TDS) is a congenital anomaly characterized by “tilting” of the optic disc tipycally associated with myopic astigmatism, visual field defect, inferior staphyloma, and retinal pigment epithelium atrophy. Associated complications such as macular serous neuroretinal det...

Descripción completa

Detalles Bibliográficos
Autores principales: Milani, Paolo, Pece, Alfredo, Pierro, Luisa, Seidenari, Patrizio, Radice, Paolo, Scialdone, Antonio
Formato: Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2995910/
https://www.ncbi.nlm.nih.gov/pubmed/21151645
http://dx.doi.org/10.1155/2010/970580
_version_ 1782193127289782272
author Milani, Paolo
Pece, Alfredo
Pierro, Luisa
Seidenari, Patrizio
Radice, Paolo
Scialdone, Antonio
author_facet Milani, Paolo
Pece, Alfredo
Pierro, Luisa
Seidenari, Patrizio
Radice, Paolo
Scialdone, Antonio
author_sort Milani, Paolo
collection PubMed
description Background. Tilted disc syndrome (TDS) is a congenital anomaly characterized by “tilting” of the optic disc tipycally associated with myopic astigmatism, visual field defect, inferior staphyloma, and retinal pigment epithelium atrophy. Associated complications such as macular serous neuroretinal detachment are well described; however, ideal therapy for such complication is unknown. Methods. One interventional case report is hereby described. A patient affected by macular serous neuroretinal detachment-complicated tilted disk syndrome underwent a complete ophthalmic examination. Optical coherence tomography and fluorescein angiography were taken at baseline and at scheduled visits. Two intravitreal treatments of bevacizumab (avastin, 1.25 mg/0.05 mL) were performed at monthly interval. Results. At scheduled visit, one month after the second injection, OCT depicted persistence of neuroretinal detachment. Best-corrected visual acuity remain stable as well as metamorphopsia and functional discomfort. Conclusion. Clinical evidence of this brief interventional case report indicates that one patient affected by recent serous macular detachment-complicated TDS did not benefit from 2 consecutive monthly intravitreal Avastin treatments. Best-corrected visual acuity remained stable over a total observation period of 6 months.
format Text
id pubmed-2995910
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-29959102010-12-13 Bevacizumab for Macular Serous Neuroretinal Detachment in Tilted Disk Syndrome Milani, Paolo Pece, Alfredo Pierro, Luisa Seidenari, Patrizio Radice, Paolo Scialdone, Antonio J Ophthalmol Case Report Background. Tilted disc syndrome (TDS) is a congenital anomaly characterized by “tilting” of the optic disc tipycally associated with myopic astigmatism, visual field defect, inferior staphyloma, and retinal pigment epithelium atrophy. Associated complications such as macular serous neuroretinal detachment are well described; however, ideal therapy for such complication is unknown. Methods. One interventional case report is hereby described. A patient affected by macular serous neuroretinal detachment-complicated tilted disk syndrome underwent a complete ophthalmic examination. Optical coherence tomography and fluorescein angiography were taken at baseline and at scheduled visits. Two intravitreal treatments of bevacizumab (avastin, 1.25 mg/0.05 mL) were performed at monthly interval. Results. At scheduled visit, one month after the second injection, OCT depicted persistence of neuroretinal detachment. Best-corrected visual acuity remain stable as well as metamorphopsia and functional discomfort. Conclusion. Clinical evidence of this brief interventional case report indicates that one patient affected by recent serous macular detachment-complicated TDS did not benefit from 2 consecutive monthly intravitreal Avastin treatments. Best-corrected visual acuity remained stable over a total observation period of 6 months. Hindawi Publishing Corporation 2010 2010-11-30 /pmc/articles/PMC2995910/ /pubmed/21151645 http://dx.doi.org/10.1155/2010/970580 Text en Copyright © 2010 Paolo Milani et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Milani, Paolo
Pece, Alfredo
Pierro, Luisa
Seidenari, Patrizio
Radice, Paolo
Scialdone, Antonio
Bevacizumab for Macular Serous Neuroretinal Detachment in Tilted Disk Syndrome
title Bevacizumab for Macular Serous Neuroretinal Detachment in Tilted Disk Syndrome
title_full Bevacizumab for Macular Serous Neuroretinal Detachment in Tilted Disk Syndrome
title_fullStr Bevacizumab for Macular Serous Neuroretinal Detachment in Tilted Disk Syndrome
title_full_unstemmed Bevacizumab for Macular Serous Neuroretinal Detachment in Tilted Disk Syndrome
title_short Bevacizumab for Macular Serous Neuroretinal Detachment in Tilted Disk Syndrome
title_sort bevacizumab for macular serous neuroretinal detachment in tilted disk syndrome
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2995910/
https://www.ncbi.nlm.nih.gov/pubmed/21151645
http://dx.doi.org/10.1155/2010/970580
work_keys_str_mv AT milanipaolo bevacizumabformacularserousneuroretinaldetachmentintilteddisksyndrome
AT pecealfredo bevacizumabformacularserousneuroretinaldetachmentintilteddisksyndrome
AT pierroluisa bevacizumabformacularserousneuroretinaldetachmentintilteddisksyndrome
AT seidenaripatrizio bevacizumabformacularserousneuroretinaldetachmentintilteddisksyndrome
AT radicepaolo bevacizumabformacularserousneuroretinaldetachmentintilteddisksyndrome
AT scialdoneantonio bevacizumabformacularserousneuroretinaldetachmentintilteddisksyndrome